StreetInsider.com News Articles

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Thu, 05 Mar 2026 16:01:00 -0500

SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results.

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Thu, 05 Mar 2026 16:01:00 -0500

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Thu, 05 Mar 2026 16:01:00 -0500

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Thu, 05 Mar 2026 16:01:00 -0500

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Mon, 23 Feb 2026 16:01:00 -0500

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET.

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Mon, 23 Feb 2026 16:01:00 -0500

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Mon, 23 Feb 2026 16:01:00 -0500

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Mon, 23 Feb 2026 16:01:00 -0500

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus

Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: MILLER RICHARD A MD

Fri, 13 Feb 2026 16:33:00 -0500

si-local-file:///var/storage/secattach/20260213/26001111.html

Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: MILLER RICHARD A MD

Fri, 13 Feb 2026 16:33:00 -0500

si-local-file:///var/storage/secattach/20260213/26001111.html

Form SCHEDULE 13D/A Corvus Pharmaceuticals, Filed by: ADAMS STREET PARTNERS LLC

Thu, 05 Feb 2026 10:30:00 -0500

si-local-file:///var/storage/secattach/20260205/25952476.html

Form SCHEDULE 13D/A Corvus Pharmaceuticals, Filed by: ADAMS STREET PARTNERS LLC

Thu, 05 Feb 2026 10:30:00 -0500

si-local-file:///var/storage/secattach/20260205/25952476.html

Form 4 Corvus Pharmaceuticals, For: Jan 28 Filed by: Thompson Peter A.

Fri, 30 Jan 2026 18:39:00 -0500

si-local-file:///var/storage/secattach/20260130/25924901.html

Form 4 Corvus Pharmaceuticals, For: Jan 28 Filed by: Thompson Peter A.

Fri, 30 Jan 2026 18:39:00 -0500

si-local-file:///var/storage/secattach/20260130/25924901.html

Form SCHEDULE 13G Corvus Pharmaceuticals, Filed by: VANGUARD GROUP INC

Fri, 30 Jan 2026 13:26:00 -0500

si-local-file:///var/storage/secattach/20260130/25922043.html

Form SCHEDULE 13G Corvus Pharmaceuticals, Filed by: VANGUARD GROUP INC

Fri, 30 Jan 2026 13:26:00 -0500

si-local-file:///var/storage/secattach/20260130/25922043.html

Corvus Pharmaceuticals (CRVS) PT Raised to $30 at Mizuho

Thu, 29 Jan 2026 06:41:54 -0500

Mizuho analyst Graig Suvannavejh raised the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $30.00 (from $20.00) while maintaining a Outperform rating.

Form SCHEDULE 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC

Tue, 27 Jan 2026 20:39:00 -0500

si-local-file:///var/storage/secattach/20260127/25902318.html

Form SCHEDULE 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC

Tue, 27 Jan 2026 20:39:00 -0500

si-local-file:///var/storage/secattach/20260127/25902318.html

Corvus Pharmaceuticals closes $201 million stock offering